Research Papers:

Targeting CD13 (aminopeptidase-N) in turn downregulates ADAM17 by internalization in acute myeloid leukaemia cells

Sandrine Bouchet, Ruoping Tang, Fanny Fava, Ollivier Legrand and Brigitte Bauvois _

PDF  |  HTML  |  How to cite

Oncotarget. 2014; 5:8211-8222. https://doi.org/10.18632/oncotarget.1788

Metrics: PDF 2745 views  |   HTML 3771 views  |   ?  


Sandrine Bouchet1, Ruoping Tang2,3, Fanny Fava2,3, Ollivier Legrand2,3 and Brigitte Bauvois1

1 INSERM U1138, Université Pierre et Marie Curie, Université Paris-Descartes, Centre de Recherche des Cordeliers, Paris, France

2 INSERM U938, Centre de Recherche de Saint-Antoine, Paris, France

3 Service d’Hématologie, Hôpital St Antoine, Paris, France


Brigitte Bauvois, email:

Keywords: myeloid leukaemia, a disintegrin and metalloproteinase, matrix metalloproteinase, tumour necrosis factor-α-converting enzyme, oncogenesis

Received: January 6, 2014 Accepted: February 17, 2014 Published: February 18, 2014


Secreted matrix metalloproteinases (MMP)-2 and MMP-9 and membrane-anchored aminopeptidase-N/CD13 are abnormally expressed in human acute myeloid leukaemia (AML). We previously showed that CD13 ligation by anti-CD13 monoclonal antibodies can induce apoptosis in AML cells. Here, we assessed ADAM17 expression in primary blood blasts CD13+CD33+ from patients with AML. Primary AML cells expressed ADAM17 transcript and its surface expression was higher in subtype M4 (myelomonocytic) and M5 (monocytic) AML specimens than in M0 and M1/M2 (early and granulocytic) specimens. In AML cell lines defining distinct AML subfamilies (HL-60/M2, NB4/M3, THP-1/M5, U937/M5) and primary AML cells cultured ex vivo, anti-CD13 antibodies downregulated surface CD13 and ADAM17 without affecting MMP-2/-9 release. Knockdown of CD13 by siRNA prevented anti-CD13-mediated ADAM17 downregulation, indicating that CD13 is required for ADAM17 downregulation. Soluble ADAM17 was not detected in the medium of anti-CD13 treated cells, suggesting that ADAM17 was not shed. After ligation by anti-CD13, CD13 and ADAM17 were internalized. Subsequently, we found that ADAM17 interacts with CD13. We postulate that the interaction of ADAM17 with CD13 and its downregulation following CD13 engagement has important implications in AML for the known roles of ADAM17 in tumour-associated cell growth, migration and invasion.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 1788